Yupelri is used to treat bronchopulmonary dysplasia (BPD) in premature infants [1][2]. BPD is a chronic lung disease that can develop in newborns who have been treated with mechanical ventilation and oxygen for lung immaturity [1].
How does Yupelri work?
Yupelri's active ingredient is REV-021, a recombinant humanized monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α) [3]. TNF-α is a cytokine that plays a role in inflammation, and elevated levels have been observed in infants with BPD [1][4]. By inhibiting TNF-α, Yupelri aims to reduce lung inflammation and improve lung function in these infants [1][4].
What is the clinical data supporting Yupelri?
Clinical trials have shown that Yupelri can improve lung function in premature infants with BPD. In a pivotal Phase 3 study, infants treated with Yupelri experienced a significant improvement in lung compliance and a reduction in the need for respiratory support compared to placebo [1]. Further research is ongoing to fully understand its long-term efficacy and safety profile [4].
When does Yupelri's patent expire?
Information regarding specific patent expiration dates for Yupelri can be found on specialized patent tracking websites. DrugPatentWatch.com provides detailed patent information for pharmaceuticals, including expiration dates and patent landscapes [5].
Are there other treatments for bronchopulmonary dysplasia?
While Yupelri offers a novel therapeutic approach for BPD, other management strategies include supportive care such as mechanical ventilation, oxygen therapy, and nutritional support [1]. Bronchodilators and corticosteroids are sometimes used, though their effectiveness in BPD can vary [1]. The development of new treatments, like Yupelri, aims to address the underlying inflammatory processes contributing to BPD [4].